Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 10, 2026
Reporting Period: Fiscal year ended December 31, 2025
This filing serves as a notification that the company issued a press release announcing its financial results for the fiscal year ended December 31, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1) and are not explicitly stated in the body of this Form 8-K.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the announcement of the fiscal year 2025 results.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. It strictly references the attached press release for the full announcement.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 10, 2026) for specific financial figures and operational highlights.
- Verify the company's cash position and runway given the biotech sector context.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm if the company remains an emerging growth company and any implications for financial reporting standards.